← All trials
NCT02712983
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 2, 2017
- Primary completion
- Sep 10, 2018
- Completion date
- Sep 10, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 180
- Arms / groups
- 9 / —
- Source
- AACT · pre-existing
Sponsors
- NovartisLead sponsor
- NovartisStudy director
- University of MilanCollaborator
- University of DundeeCollaborator
- University of EdinburghCollaborator
- University of AntwerpCollaborator
- Papworth Hospital NHS Foundation TrustCollaborator
- University of LondonCollaborator
- Queen's University, BelfastCollaborator
- Erasmus University RotterdamCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.